Notícias e Atividades da Galectin Therapeutics

Galectin Therapeutics é uma empresa listada sob o símbolo GALT (US).

Veja o organograma con seus 20 executivos principais

Biografias mais buscadas da Galectin Therapeutics

• Joel Lewis, President, Chief Executive Officer and Director
• Kevin Freeman, Vice Chairman of the Board
• Henry Brem, Independent Director

Recentes movimentos de executivos em Galectin Therapeutics

• Henry Brem, ingressou na Companhia como Independent Director  (Notícia publicada em 18 de março de 2026).

Criar um alerta
para seguir os movimentos de executivos da Galectin Therapeutics.

Galectin Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Galectin Therapeutics

• Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 | Galectin Therapeutics Inc.
• Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 | Galectin Therapeutics Inc.
• Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress | Galectin Therapeutics Inc.
• Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today | Galectin Therapeutics Inc.
• Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 | Galectin Therapeutics Inc.
• Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 | Galectin Therapeutics Inc.
• Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer | Galectin Therapeutics Inc.
• Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update | Galectin Therapeutics Inc.
• Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
• UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
• View more press releases Close

Redes sociais sobre Galectin Therapeutics

• Galectin Therapeutics na Wikipedia, Google News e Yahoo Finance
• Galectin Therapeutics na LinkedIn, X (Twitter) e YouTube